Medivolve Inc. MEDVF
OTC PK
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 214.20K | 188.20K | 136.20K | 144.10K | 54.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 214.20K | 188.20K | 136.20K | 144.10K | 54.10K |
| Cost of Revenue | 19.50K | 28.90K | 34.40K | -119.70K | 26.00K |
| Gross Profit | 194.70K | 159.30K | 101.80K | 263.80K | 28.10K |
| SG&A Expenses | 541.40K | 556.80K | 964.20K | 1.95M | 773.70K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 560.90K | 585.70K | 998.60K | 1.83M | 799.70K |
| Operating Income | -346.70K | -397.50K | -862.40K | -1.69M | -745.60K |
| Income Before Tax | -489.00K | -389.60K | -824.60K | -1.25M | -1.18M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -489.00K | -389.60K | -824.60K | -1.25M | -1.18M |
| Earnings from Discontinued Operations | -255.50K | -5.81M | -1.89M | -- | -968.20K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 53.20K | 39.80K | 100.60K | -- | -- |
| Net Income | -691.30K | -6.16M | -2.62M | -1.25M | -2.15M |
| EBIT | -346.70K | -397.50K | -862.40K | -1.69M | -745.60K |
| EBITDA | -322.30K | -374.00K | -696.20K | -1.67M | -628.30K |
| EPS Basic | -0.03 | -0.23 | -0.10 | -0.05 | -0.08 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.02 | -0.04 | -0.02 |
| EPS Diluted | -0.03 | -0.23 | -0.10 | -0.05 | -0.08 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.02 | -0.04 | -0.02 |
| Average Basic Shares Outstanding | 27.02M | 27.02M | 27.02M | 27.02M | 27.02M |
| Average Diluted Shares Outstanding | 27.02M | 27.02M | 27.02M | 27.02M | 27.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |